Raise large amounts of capital with an initial public offering, burn cash while navigating clinical trials, then submit a new ...

The First Trust NYSE Arca Biotechnology ETF (FBT) was launched on June 19, 2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of ...

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. When it comes to biotech ETFs, they give sector participants exposure to many biotech companies via one ...

The State Street SPDR S&P Biotech ETF (XBI) was launched on January 31, 2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of ...

Although the equities market often embodies chaos and capricious non-linearity, few sectors witness as much kinetic wildness like biotechnology. At its core, biotech represents an innovative push ...

For investors seeking momentum, State Street SPDR S&P Biotech ETF XBI is probably on the radar. The fund just hit a 52-week high and has risen 98.15% from its 52-week low price of $66.66/share. But ...

There is no denying that the pandemic has opened up investment opportunities in the biotech sector by triggering a race to introduce vaccines and treatment options. Moreover, increasing mergers and ...

Investment giant KKR & Co. Inc. (NYSE: KKR) is advising investors to look past the crowded trades of the U.S. large-cap market for the next phase of growth. In its “High Grading” Outlook for 2026, the ...